Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | GAPDH | P04406 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525776 | 0.89 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL13268818 | 0.89 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL13269091 | 0.89 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL13268769 | 0.85 | INMT (0.43) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| Benzene SCHEMBL27650186 | 0.85 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL29721329 | 0.85 | ADORA3 (0.50) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL7435441 | 0.85 | ADORA3 (0.50) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL10345562 | 0.85 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL13269464 | 0.85 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL2270700 | 0.84 | ADORA2A (0.51) | PI4KAPI4K2BPI4K2API4KBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9320753-B2 | Organ arrest, protection and preservation | HIBERNATION THERAPEUTICS, A KF LLC (US) | 2016-04-26 | — | — | US | claimed |
| US-20130184231-A1 | ORGAN ARREST, PROTECTION AND PRESERVATION | HIBERNATION THERAPEUTICS LIMITED (AU) | 2013-07-18 | — | — | US | claimed |
| US-20100298254-A1 | ORGAN ARREST, PROTECTION AND PRESERVATION | HIBERNATION THERAPEUTICS LIMITED (AU) | 2010-11-25 | — | — | US | claimed |
| US-20070270372-A1 | arresting heart of subject in need of heart surgery by exposing heart to effective amounts of a compound chosen from a potassium channel opener, a potassium channel agonist, an adenosine receptor agonist, and a local anaesthetic under conditions sufficient for heart to be arrested | HIBERNATION THERAPEUTICS LIMITED (AU) | 2007-11-22 | — | — | US | claimed |
| US-7223413-B2 | Composition of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine | HIBERNATION THERAPEUTICS LIMITED (AU) | 2007-05-29 | — | — | US | claimed |
| EP-1168912-B1 | ORGAN ARREST, PROTECTION AND PRESERVATION | HIBERNATION THERAPEUTICS LTD (AU) | 2007-05-09 | — | — | EP | claimed |
| US-6955814-B1 | protecting and/or preserving organs, in particular the heart during open-heart surgery, cardiovascular diagnosis or therapeutic intervention by administering potassium channel opener or agonist and adenosine receptor agonist and local anesthetic | GLOBAL CARDIAC SOLUTIONS PTY LTD. (AU) | 2005-10-18 | — | — | US | claimed |
| US-20050171050-A1 | Composition of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine | GLOBAL CARDIAC SOLUTIONS PTD. LTD. (AU) | 2005-08-04 | — | — | US | claimed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-23 | — | — | US | disclosed |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220265282-A1 | USE OF REMOTE ISCHEMIC CONDITIONING FOR TRAUMATIC INJURY | THE HOSPITAL FOR SICK CHILDREN (CA) | 2022-08-25 | — | — | US | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| US-11045207-B2 | Use of remote ischemic conditioning for traumatic injury | THE HOSPITAL FOR SICK CHILDREN (CA) | 2021-06-29 | — | — | US | disclosed |
| US-20090324748-A1 | TRAUMA THERAPY | HIBERNATION THERAPEUTICS LIMITED (AU) | 2009-12-31 | — | — | US | disclosed |
| EP-2079301-A1 | IMPROVED TISSUE MAINTENANCE | Hibernation Therapeutics Limited (AU) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009012534-A1 | IMPROVED ORGAN PROTECTION, PRESERVATION AND RECOVERY | HIBERNATION THERAPEUTICS LIMITED (AU) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008106724-A1 | TRANSPLANTS | HIBERNATION THERAPEUTICS LIMITED (AU) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007137321-A1 | IMPROVED TISSUE MAINTENANCE | HIBERNATION THERAPEUTICS LIMITED (AU) | 2007-12-06 | — | — | WO | disclosed |
| US-6955814-B1 | protecting and/or preserving organs, in particular the heart during open-heart surgery, cardiovascular diagnosis or therapeutic intervention by administering potassium channel opener or agonist and adenosine receptor agonist and local anesthetic | GLOBAL CARDIAC SOLUTIONS PTY LTD. (AU) | 2005-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | PI4KA 3210/4885PI4K2B 2991/4885PI4K2A 2993/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | PI4KA 3210/4885PI4K2B 2991/4885PI4K2A 2993/4885 |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | MKI67, MYLK2, MYH2 | PI4KA 3210/4885PI4K2B 2991/4885PI4K2A 2993/4885 |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | MKI67, CDK4, CDKN1A | PI4KA 1246/4885PI4K2B 1161/4885PI4K2A 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.